|
Discurso inaugural del Dr. Eduardo Ticona Chavez |
 |
 |
 |
|
Wednesday, 29 July 2009 00:00 |
Presidente de la Sociedad Peruana de Enfermedades Infecciosas y Tropicales
 Me dirijo a ustedes, a nombre de la Junta Directiva electa de la SPEIT. En primer termino para agradecerles por acompañarnos en este acto, y ser testigos del compromiso que esta JD asume dentro de la SPEIT.
Todos conocemos que el desarrollo de una nación, es producto del desarrollo de sus instituciones. Como ciudadanos de nuestro país pertenecemos y hemos pertenecido a diferentes instituciones a lo largo de nuestra vida, llámese escuelas, universidades, etc. y actualmente hospitales, universidades, dependencias del MINSA, Essalud, ONGs, Industria farmacéutica, clínicas privadas, etc. Así, si estas son fuertes y sólidas, será poderoso nuestro país. Ya que todos contribuimos necesariamente al desarrollo de nuestro Perú.
|
|
Last Updated on Monday, 27 September 2010 22:13 |
|
Read more...
|
|
50th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC)
September 12 - 15, 2010; Boston, Massachusetts
Conferences News:
ICAAC Antibiotic Prescribing Habits Have Shifted According to Pathogen Prevalence Patterns
Medscape Medical News, September 22, 2010
ICAAC Bone Loss Evident in Nearly Half of HIV-Positive Patients on Antiretroviral Therapy
Medscape Medical News, September 22, 2010
ICAAC NDM-1 Gene Spreading to Multiple Bacteria Species, Making Them Antibiotic-Resistant
Medscape Medical News, September 22, 2010
ICAAC Infections Common in Patients With Ventricular Assist Devices
Medscape Medical News, September 21, 2010
|
|
Read more...
|
Lopinavir Monotherapy: High Risk for Viral Relapse in the Central Nervous System
Switching to lopinavir/ritonavir monotherapy was associated with a high failure rate and with elevated viral loads in the cerebrospinal fluid.
Combination antiretroviral therapy has substantially reduced HIV morbidity and mortality, but the adverse effects and cost of multiple drugs remain a concern, prompting interest in treatment simplification. Because of its high resistance barrier, boosted lopinavir has been considered an attractive option for simplified maintenance therapy
In this open-label trial, researchers randomized 60 patients who had viral loads <50 copies/mL for at least 3 months to either continue their triple-drug therapy or switch to lopinavir/r monotherapy. The primary endpoint was treatment failure in the central nervous system (CNS) and/or genital tract.
|
|
Read more...
|
|
|
